The FTSE 100 pharmaceutical giant has upgraded its profit forecast for the full year, boosted by strong sales of asthma medicine and the shingles vaccine. Revenue reached £7.4bn in the first quarter, up 10%.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.